2 news items
Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress
INVA
8 May 24
on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. Innoviva's other innovative healthcare assets include infectious
Innoviva to Participate in the BofA Securities Health Care Conference
INVA
8 May 24
is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. Innoviva's other innovative
- Prev
- 1
- Next